CAMBRIDGE, Mass., July 19 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. will hold a live webcast of a conference call at 8:00 a.m. ET on Thursday, July 26, 2007. Senior management will discuss the Company’s second-quarter 2007 financial and operational results and upcoming activities. A presentation to accompany the conference call will be available on the webcast. Prior to the conference call on Thursday, July 26, 2007, the Company will announce its financial results for the period in a press release.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The press release, presentation and live webcast can be accessed by visiting the Investors section of the Company’s website, http://www.millennium.com. Following the webcast, an archived version of the call and presentation will be available at the same address for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company’s research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company’s website is http://www.millennium.com.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: http://www.millennium.com.
Contact: Kyle Kuvalanka Investor Relations (617) 761-4734
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comMillennium Pharmaceuticals, Inc.
CONTACT: Kyle Kuvalanka, Investor Relations for MillenniumPharmaceuticals, Inc., +1-617-761-4734
Web site: http://www.millennium.com/
Company News On-Call: http://www.prnewswire.com/comp/114562.html/
